Unclaimed brand
Removing barriers with innovative science to deliver effective treatments for people living with serious psychiatric illness. Restoring hope and stability to enable fuller lives. OUR MISSION Driving innovative science to deliver safer and more effective psychiatric treatments to patients – faster Amani’s lead program, AM-01, is a fixed-dose combination product that includes clozapine and a […]
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#DAD0EC
Snuff
218, 208, 236
261, 42, 87
8, 12, 0, 7
#646EB9
Blue Violet
100, 110, 185
233, 38, 56
46, 41, 0, 27
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
Amani Therapeutics is a biotechnology company focused on developing innovative treatments for people living with serious psychiatric illnesses. Its mission is to advance safer, more effective psychiatric care and help patients achieve greater stability and fuller lives.
The company’s lead program, AM-01, is a fixed-dose combination of clozapine and a Phase 3-ready new chemical entity, licensed worldwide from AstraZeneca. Amani is developing AM-01 with the goal of preserving clozapine’s efficacy for people with schizophrenia while addressing severe neutropenia, a serious safety concern, and the demanding blood-monitoring requirements associated with treatment. Clozapine is the only medication described by the company as proven to meaningfully improve symptoms in treatment-resistant schizophrenia and reduce suicide risk in people with schizophrenia and schizoaffective disorder, yet these safety and monitoring burdens limit its use. AM-01 is an investigational program, not a treatment identified as approved.
Amani’s team includes leaders in clinical medicine, operations, development, manufacturing, regulatory affairs, and alliance management.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
